<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://openbell.ai/</loc>
    <lastmod>2026-11-20T13:37:09.028Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://openbell.ai/support</loc>
    <lastmod>2026-11-20T13:37:09.028Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://openbell.ai/privacy</loc>
    <lastmod>2026-11-20T13:37:09.028Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/terms</loc>
    <lastmod>2026-11-20T13:37:09.028Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/feed.json</loc>
    <lastmod>2026-11-20T13:37:09.028Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://openbell.ai/news/CBK:1795179773000</loc>
    <lastmod>2026-11-20T13:02:53.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/CBK/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Commerzbank Raises 2026 Net Profit Outlook</image:title>
      <image:caption>Commerzbank CEO Bettina Orlopp raised the bank’s 2026 net profit outlook to €3.5 billion, up from guidance of at least €3.4 billion. The revision reflects better-than-expected cost performance and favorable tax developments; the article reports no stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BTS:1795179728000</loc>
    <lastmod>2026-11-20T13:02:08.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BTS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>BTV Vier Länder Bank AG Reports Strong Growth for Q3 2026</image:title>
      <image:caption>BTV Vier Länder Bank AG reported Q3 2026 pre-tax earnings of €188.5 million, up €22.4 million from the same period last year. Managed customer deposits increased by €2.2 billion to €23.4 billion, while equity exceeded €2.8 billion for the first time. CEO Gerhard Burtscher credited the results to the bank’s capital strength, financial stability and long-term strategic focus.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/UQA:1795179711000</loc>
    <lastmod>2026-11-20T13:01:51.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/UQA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>UNIQA Raises Full-Year Profit Outlook Following Strong Nine-Month Results</image:title>
      <image:caption>UNIQA Insurance Group reported that nine-month 2026 premiums rose 9.2% to €7 billion, including a 3.1% increase in life premiums to more than €1.3 billion. Pre-tax earnings climbed over 17% to €495 million, while natural-disaster losses totaled €80 million. The company raised its full-year profit forecast to €590 million–€610 million from €540 million–€570 million, citing stronger results and lower-than-expected disaster impacts. CEO Andreas Brandstetter pointed to renewed life-insurance demand and the need to price climate-related risks appropriately.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/VK:1795179711000</loc>
    <lastmod>2026-11-20T13:01:51.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/VK/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Vallourec Reports Q3 2026 Results and Issues Disappointing Q4 Outlook</image:title>
      <image:caption>Vallourec reported third-quarter 2026 results and forecast fourth-quarter EBITDA of $170 million to $210 million, with a $190 million midpoint about 25% below Visible Alpha consensus of $253 million. It cited U.S. operational disruptions and additional Middle East-related shipping costs. The company now expects full-year 2026 EBITDA of $760 million to $800 million, roughly 8% below consensus, and its stock fell significantly after the announcement.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BILL:1795177971000</loc>
    <lastmod>2026-11-20T12:32:51.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BILL/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>BILL Holdings, Inc. Enters Definitive Agreement to be Acquired by TPG and Corpay</image:title>
      <image:caption>BILL Holdings entered into a definitive agreement to be acquired by TPG in partnership with Corpay. BILL shareholders will receive $63.25 per share in cash, valuing the company at approximately $6.0 billion. The transaction, which would change ownership of the financial operations platform serving nearly 500,000 businesses, is subject to customary closing conditions and regulatory approvals.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/ERAS:1795177942000</loc>
    <lastmod>2026-11-20T12:32:22.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/ERAS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Erasca Reports Positive Phase 1 Clinical Data for Pan-RAS Molecular Glue ERAS-0015</image:title>
      <image:caption>Erasca reported updated Phase 1 data for investigational pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. At a 32 mg once-daily dose, the therapy achieved a 44% confirmed objective response rate among patients with second-line-or-later KRAS G12X pancreatic ductal adenocarcinoma, including many heavily pretreated patients and those with G12R mutations. The company also reported favorable safety data and plans to initiate a potentially registration-enabling study; the article did not provide financial results or stock-price movements.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BA:1795177931000</loc>
    <lastmod>2026-11-20T12:32:11.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BA/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Northrop Grumman Will Not Contest Boeing&#39;s $20 Billion F/A-XX Navy Contract</image:title>
      <image:caption>Northrop Grumman will not challenge the U.S. Navy’s decision to award Boeing the $20 billion F/A-XX fighter jet contract. The decision removes a potential hurdle for the program to develop the Navy’s next-generation carrier-based aircraft and gives Boeing’s defense division a key role in the Navy’s future air combat strategy.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BJ:1795177930000</loc>
    <lastmod>2026-11-20T12:32:10.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BJ/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>BJ&#39;s Wholesale Club Reports Fiscal Q3 2026 Financial Results</image:title>
      <image:caption>BJ&#39;s Wholesale Club reported fiscal Q3 2026 adjusted EPS of $1.73, above the FactSet consensus of $1.26. Revenue totaled $6.28 billion, exceeding the $5.97 billion estimate. The company projected fiscal 2026 adjusted EPS of $5.10–$5.30, compared with analyst consensus of $4.74.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/FFIV:1795177924000</loc>
    <lastmod>2026-11-20T12:32:04.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/FFIV/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>F5 Discloses Critical Vulnerabilities in BIG-IP Products</image:title>
      <image:caption>F5 disclosed six critical vulnerabilities in its BIG-IP network traffic management products. The company said it knows of no exploitation or service disruptions, but warned that unauthenticated attackers could potentially disrupt services or execute remote code. F5 advised customers to install available engineering hotfixes while it prepares further patches; the products are used across sectors, including healthcare.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/HAS:1795177906000</loc>
    <lastmod>2026-11-20T12:31:46.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/HAS/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Hasbro Raises Fiscal 2026 Financial Guidance and Doubles Share Repurchase Target</image:title>
      <image:caption>Hasbro raised its fiscal 2026 revenue growth outlook to 7%–9% in constant currency, from 5%–7% previously. It also increased its adjusted operating margin guidance to 27%–28% and its adjusted EBITDA outlook to $1.575 billion–$1.625 billion. The company doubled its share repurchase target for the year, citing strong business momentum and a focus on balancing investment with shareholder returns.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/UTHR:1795177902000</loc>
    <lastmod>2026-11-20T12:31:42.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/UTHR/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>United Therapeutics Announces First Clinical Xenotransplant in EXTEND Study</image:title>
      <image:caption>United Therapeutics announced the first clinical xenotransplant in its EXTEND study, which is evaluating the safety and efficacy of its UThymoKidney in patients with end-stage renal disease. The procedure was performed at NYU Langone Health, with the study targeting patients who are ineligible for conventional kidney transplantation or need alternative treatment options. The company described the milestone as a step forward in its organ-manufacturing and xenotransplantation research; the article reported no financial results or stock-price impact.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/MRK:1795177892000</loc>
    <lastmod>2026-11-20T12:31:32.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/MRK/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan Met Primary Endpoint</image:title>
      <image:caption>Merck said its Phase 3 TroFuse-015 trial of investigational sacituzumab tirumotecan met its primary endpoint of overall survival in patients with third-line or later locally advanced unresectable or metastatic gastroesophageal adenocarcinoma. The company said further trial data and clinical implications will be presented at upcoming medical forums. The announcement marks a development in Merck’s oncology pipeline; no financial results or stock-price impact were reported.</image:caption>
    </image:image>
  </url>
</urlset>